Download PDF
Klin Monbl Augenheilkd 2008; 225(7): 653-659
DOI: 10.1055/s-2008-1027455
Klinische Studie

© Georg Thieme Verlag KG Stuttgart · New York

Photodynamische Therapie kombiniert mit intravitrealer Injektion von Bevacizumab zur Behandlung okkulter und klassischer choroidaler Neovaskularisationen bei AMD

Photodynamic Therapy with Verteporfin Combined with Intravitreal Injection of Bevacizumab for Occult and Classic CNV in AMDM. Maier1 , K. Haas1 , N. Feucht1 , B. Fiore1 , C. Winkler von Mohrenfels1 , A. Clos1 , C. Lohmann1
  • 1Augenklinik, Klinikum rechts der Isar der TU München
Further Information

Publication History

Eingegangen: 14.11.2007

Angenommen: 3.3.2008

Publication Date:
18 July 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Besonders okkulte choroidale Neovaskularisationen (CNV) mit Pigmentepithelabhebung (PED) zeigen nach Standard-PDT oft eine Vergrößerung der PED oder einen RPE-Riss. Untersucht wird der Effekt einer Kombination von photodynamischer Therapie (PDT) und intravitrealer Behandlung mit Bevacizumab bei okkulter und klassischer choroidaler Neovaskularisation (CNV) bei AMD. Methoden: In einer Pilotstudie wurden 23 Patienten mit okkulter oder klassischer CNV bei AMD mit intravitrealer Injektion von Bevacizumab (1,25 mg) 12 bis 24 Stunden nach Standard-PDT behandelt. Vor, 1, 3 und 6 Monate nach Behandlung wurden Sehschärfe und mit dem OCT die Netzhautdicke untersucht. Ergebnisse: Die mittlere Sehschärfe verbesserte sich im Vergleich zur Ausgangssehschärfe signifikant. (Visus vor Behandlung = 0,16, nach 1 Monat 0,26, nach 3 Monaten 0,25 und 0,25 nach 6 Monaten). Wir fanden keinen RPE-Riss. Die OCT-Untersuchung 1, 3 and 6 Monate nach Kombinationstherapie zeigte eine Reduktion der Netzhautdicke. Schlussfolgerung: Eine photodynamische Therapie kombiniert mit intravitrealer Applikation von Bevacizumab scheint aufgrund des Anti-VEGF- und des antientzündlichen Effektes von Bevacizumab wirksamer zu sein als eine PDT-Monotherapie. Unsere Kurzzeitergebnisse sind vielversprechend. Weitere Untersuchungen sind nötig, um den Langzeiteffekt der Kombinationstherapie von PDT und intravitrealer Anti-VEGF-Therapie zu überprüfen.

Abstract

Purpose: The aim of this study is to discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab (1.25 mg) in occult and classic choroidal neovascularisation (CNV) due to AMD. Especially cases of occult CNV with pigment epithelium detachment (PED) are not likely to respond positively to standard photodynamic therapy, often ending up in PED enlargement or tearing of the RPE. Methods: In a pilot study involving 23 patients, intravitreal injections of bevacizumab were administered within 12 to 24 hours after standard PDT to reduce the post-PDT increase of proangiogenic and inflammatory factors. Before and at 1, 3 and 6 month after treatment visual acuity and OCT examinations (retinal thickness) were performed. Results: Mean visual acuity was significantly improved compared to baseline. (VA baseline 20 / 125, after 1 month 20 / 80, after 3 months 20 / 80, and 20 / 80 after 6 months) and an enlargement of the PED in occult CNV was prevented. We found no RPE rip. OCT findings in patients with occult and classic choroidal neovascularisation 1, 3 and 6 months after combination therapy showed a reduced retinal thickness compared to baseline. Conclusions: Photodynamic therapy combined with injection of intravitreal bevacizumab tends to be more effective compared to PDT monotherapy by reducing the post-PDT increase of vascular growth and inflammatory factors. Our short-term results are very promising. Further studies are necessary to show the long-term effect of PDT and anti-VEGF combination therapy.

Schlüsselwörter

Retina - Glaskörper - Chorioidea

Key words

retina - vitreous - choroid

Literatur

  • 1 Aiello L P, Brucker A J, Chang S. et al . Evolving guidelines for intravitreous injections.  Retina. 2004;  24 S3-S19
    Google Scholar
  • 2 Augustin A J, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.  Ophthalmology. 2006;  113 14-22
    Google Scholar
  • 3 Avery R L, Pieramici D J, Rabena M D. et al . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.  Ophthalmology. 2006;  113 363-372
    Google Scholar
  • 4 Bernatchez P N, Rollin S, Soker S. et al . Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1.  J Cell Biochem. 2002;  85 629-639
    Google Scholar
  • 5 Blinder K J, Bradley S, Bressler N M. et al . Effekt of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choridal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.  Am J Ophthalmol. 2003;  136 407-418
    Google Scholar
  • 6 Brown D M, Kaiser P K, Michels M. et al . ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 (14) 1432-1444
    Google Scholar
  • 7 Costa R A, Jorge R, Calucci D. et al . Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IbeVe Study).  Graefes Arch Clin Exp Ophthalmol. 2007;  245 (9) 1273-1280
    Google Scholar
  • 8 Dhalla M S, Shah G K, Blinder K J. et al . Combined photodynamic therapy with verteporfin and intravitreal bevazicumab for choroidal neovascularization in age-related macular degeneration.  Retina. 2006;  26 (9) 988-993
    Google Scholar
  • 9 Goldstein M, Heilweil G, Barak A. et al . Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD.  Eye. 2005;  19 (12) 1315-1324
    Google Scholar
  • 10 Gragoudas E S, Adamis A P, Cunningham E T Jr. et al . VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration.  N Engl J Med. 2004;  351 (27) 2805-2816
    Google Scholar
  • 11 Heier J S, Boyer D S, Ciulla T A. et al . FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.  Arch Ophthalmol. 2006;  124 (11) 1532-1542
    Google Scholar
  • 12 Heier J S, Antoszyk A N, Pavan P R. et al . Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.  Ophthalmology. 2006;  113 633. e1–e4. Epub 2006 Feb. 14
    Google Scholar
  • 13 Hussain D, Kramer M, Kenny A G. et al . Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment.  Invest Ophthalmol Vis Sci. 1999;  40 2322-2331
    Google Scholar
  • 14 Hussain D, Kim I, Gauthier D. et al . Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.  Arch Ophthalmol. 2005;  123 509-516
    Google Scholar
  • 15 Jaissle G B, Szurman P, Bartz-Schmidt K U. Recommendation for implementation of intravitreal injections – statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German professional Association of Ophthalmologists (BVA).  Klin Monatsbl Augenheilkd. 2005;  222 390-395
    Google Scholar
  • 16 Jonas J B. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovasular diseases.  Acta Ophthamol Scand. 2005;  83 645-663
    Google Scholar
  • 17 Kim I K, Husain D, Michaud N. et al . Effekt of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid.  Invest Ophthalmol Vis Sci. 2006;  47 357-363
    Google Scholar
  • 18 Kramer M, Miller J W, Michaud N. et al . Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.  Ophthalmology. 1996;  103 427-438
    Google Scholar
  • 19 Lazic R, Gabric N, Dekaris I. et al . Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration.  Coll Antropol. 2007;  31 (Suppl 1) 71-75
    Google Scholar
  • 20 Ladewig M S, Karl S E, Hamelmann V. et al . Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.  Graefes Arch Clin Exp Ophthalmol. 2008;  246 (1) 17-25
    Google Scholar
  • 21 Michels S, Hansmann F, Geitzenauer W. et al . Influence of treatment parameters on selectivity of verteporfin therapy.  Invest Ophthalmol Vis Sci. 2006;  47 371-376
    Google Scholar
  • 22 Michels S, Rosenfeld P J, Puliafito C A. et al . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.  Ophthalmology. 2005;  112 1035-1047
    Google Scholar
  • 23 Moshfegi D M, Kaiser P K, Grossniklaus H E. et al . Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapie.  Am J Ophthalmol. 2003;  135 343-350
    Google Scholar
  • 24 Rechtman E, Danis R P, Pratt L M. et al . Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration.  Br J Ophthalmol. 2004;  88 344-347
    Google Scholar
  • 25 Rosenfeld P J, Moshfeghi A A, Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.  Ophthalmic Surg Lasers Imaging. 2005;  36 331-335
    Google Scholar
  • 26 Rosenfeld P J, Brown D M, Heier J S. et al . MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 (14) 1419-1431
    Google Scholar
  • 27 Rosenfeld P J, Rich R M, Lalwani G A. Ranibizumab: Phase III clinical trial results.  Ophthalmol Clin North Am. 2006;  19 (3) 361-372
    Google Scholar
  • 28 PROTECT Data on file. 
    Google Scholar
  • 29 Schmidt-Erfurth U, Miller J W, Sickenberg M. et al . Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.  Arch Ophthalmol. 1999;  117 1177-1187
    Google Scholar
  • 30 Schmidt-Erfurth U, Hassan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.  Surv Ophthalmol. 2000;  45 (3) 195-214
    Google Scholar
  • 31 Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U. et al . Histopathological changes following photodynamic therapy in human eyes.  Arch Ophthalmol. 2002;  120 835-844
    Google Scholar
  • 32 Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C. et al . Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.  Invest Ophthalmol Vis Sci. 2003;  44 4473-4480
    Google Scholar
  • 33 Spaide R F, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.  Ophthamology. 2003;  110 1517-1525
    Google Scholar
  • 34 Spaide R F, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.  Ophthalmology. 2005;  112 301-304
    Google Scholar
  • 35 Spaide R F, Laud K, Fine H F. et al . Intravitreal bevazicumab treatment of choroidal neovascularization secondary to age-related macular degeneration.  Retina. 2006;  26 383-390
    Google Scholar
  • 36 Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration.  Klin Monatsbl Augenheilkd. 2007;  224 (7) 559-566
    Google Scholar
  • 37 TAP Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP Report 2.  Arch Ophthalmol. 2002;  119 198-207
    Google Scholar
  • 38 Thakker G D, Hajjar D P, Muller W A. et al . The role of phospatidylinositol 3-kinase in vascular endothelial growth factor signaling.  J Biol Chem. 1999;  274 10 002-10 007
    Google Scholar
  • 39 Tzekov R, Lin T, Zhang K M. et al . Ocular changes after photodynamic therapy.  Invest Ophthalmol Vis Sci. 2006;  47 (1) 377-385
    Google Scholar
  • 40 Chakravarthy U, Adamis A P, Cunningham E T Jr. et al . VEGF Inhibition Study in Ocular Neovascularization (V. I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.  Ophthalmology. 2006;  113 (9) 1508.e1 – 25. Epub 7.7.2006
    Google Scholar

Dr. med. Mathias Martin Maier

Klinik und Poliklinik für Augenheilkunde rechts der Isar der Technischen Universität München

Ismaningerstr. 22

81675 Munich

Phone: ++ 49/89/41 40 23 40

Fax: ++ 49/89/41 40 48 58

Email: M.Maier@lrz.tum.de

      >